Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SRPT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — Current CEO Douglas Ingram is departing his executive and board positions effective July 28, 2026, described as a retirement with advisory role through year-end.
Sarepta appoints Michael Severino as CEO with $35M equity grant; Doug Ingram retires
Filed July 27, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
Michael Severino, M.D., appointed CEO effective July 28, 2026, with $1.18M base salary, 110% target bonus, and $35M sign-on equity grant including $14M make-whole for forfeited prior-employer awards.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Doug Ingram departs as CEO and board member July 28, 2026, transitioning to consultant through year-end at $15,000 monthly fee.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Severino brings 25+ years biopharmaceutical experience, most recently CEO of Tessera Therapeutics and previously Vice Chairman/President at AbbVie overseeing R&D and corporate strategy.
Exhibit 99.1 view on EDGAR → -
medium
Severance terms include 18 months base salary and target bonus for qualifying terminations outside change-of-control; 24 months salary, 2x target bonus, and full equity acceleration during change-of-control period.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Sarepta Therapeutics executed a CEO transition, appointing Michael Severino, M.D., effective July 28, 2026, as Doug Ingram retires after leading the company's evolution into a genetic medicine leader. The Board conducted a comprehensive search before selecting Severino, who brings over 25 years of biopharmaceutical experience including roles as CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie, where he oversaw R&D, corporate strategy, and contributed to over a dozen approved therapies including Rinvoq, Skyrizi, and Venclexta. The $35 million sign-on equity package is substantial, reflecting both competitive market dynamics for experienced biopharma executives and compensation for forfeited equity from Severino's prior employer ($14 million make-whole component).
The package includes prorated 2026 and full 2027 annual grants, structured as one-third RSUs and two-thirds premium-priced options vesting over four years. Ingram's departure as CEO and board member, while characterized as a retirement with a consulting transition through year-end, represents a leadership change at a company the outgoing CEO described as having "a portfolio of life-changing therapies, a pipeline with exceptional potential and the financial resources to advance that science independently and at scale." Investors should monitor Severino's strategic priorities and execution as he assumes leadership of the rare disease genetic medicine franchise.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Sarepta appoints Michael Severino, M.D. as CEO effective July 28, 2026, succeeding Douglas Ingram who departs to consulting role.
Added in current filing · verify on EDGAR →
Under the Employment Agreement, Dr. Severino is entitled to receive an annual base salary of $1,180,000 and will be eligible to participate in the Company’s bonus program with a target bonus of 110% of base salary. For 2026, Dr. Severino’s annual bonus will be paid based on performance at 100% of target and prorated based on his period of employment with the Company during the year.
Dr. Severino will receive an annual base salary of $1,180,000 with a target bonus of 110% of base salary. His 2026 bonus will be paid at 100% of target, prorated for his employment period during the year.
Added in current filing · verify on EDGAR →
In connection with Dr. Severino’s appointment as Chief Executive Officer, Dr. Severino will receive a sign-on grant of equity awards under the Company’s 2024 Employment Commencement Incentive Plan with a grant date value approximately equal to $35,000,000 (the “Sign-On Grant”). The Sign-On Grant is composed of (i) a 2026 annual equity grant with a grant date value approximately equal to $6,000,000, which represents a prorated grant for 2026, (ii) a 2027 annual equity grant with a grant date value approximately equal to $12,000,000, (iii) a new hire equity grant with a grant date value approximately equal to $3,000,000, and (iv) a make-whole equity grant with a grant date value approximately equal to $14,000,000 to compensate the Dr. Severino for relinquished equity awards from his prior employer (the “Make-Whole Grant”).
Dr. Severino will receive a sign-on equity grant valued at approximately $35,000,000, composed of four components: a prorated 2026 annual grant ($6,000,000), a 2027 annual grant ($12,000,000), a new hire grant ($3,000,000), and a make-whole grant ($14,000,000) to compensate for equity forfeited from his prior employer. The grant consists of approximately $35,000,000 one-third restricted stock units vesting over four years and two-thirds premium priced stock options vesting over four years with 25% on the first anniversary.
Added in current filing · verify on EDGAR →
Under the Employment Agreement, upon an involuntary termination of employment without Cause, including a non-renewal of the employment term by the Company, or a voluntary termination of employment for Good Reason (each as defined in the Employment Agreement and such termination, a “qualifying termination”), in each case not in the period beginning six-months before and ending 24 months following a change of control (the “change of control period”), Dr. Severino is entitled to (i) 18 months of base salary payable in the form of salary continuation, (ii) his target annual bonus for the year of termination, payable over the 18-month severance term, (iii) any earned but unpaid annual bonus for the year prior to the year of termination, (iii) a pro-rata annual bonus based upon actual performance and paid at the same time bonuses are paid to other Company executives (a “Pro-Rata Bonus”), (iv) payment by the Company of the employer cost of COBRA for up to 18 months, and (v) outplacement services at a value not to exceed $20,000.
Dr. Severino's employment agreement includes severance provisions for qualifying terminations outside a change of control period: 18 months base salary continuation, target annual bonus for the termination year, pro-rata bonus based on actual performance, COBRA coverage for up to 18 months, and outplacement services up to $20,000. For qualifying terminations during a change of control period, he receives enhanced benefits including 24 months base salary and two times target bonus in a lump sum, plus full acceleration of all unvested time-based equity awards.
Added in current filing · verify on EDGAR →
Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date. Mr. Ingram and the Company entered into a Consulting Agreement, dated July 26, 2026 (the “Consulting Agreement”), pursuant to which he will serve as consultant to the Company until December 31, 2026 in exchange for a monthly consulting fee of $15,000.
Douglas Ingram will depart as CEO and Board member effective July 28, 2026. He will serve as a consultant to the Company through December 31, 2026, receiving a monthly consulting fee of $15,000.
Event · Item 7.01 — Regulation FD Disclosure
Sarepta appointed Dr. Severino as Chief Executive Officer, disclosed via press release furnished as Exhibit 99.1.
Added in current filing · verify on EDGAR →
The Company issued a press release in connection with the announcement of Dr. Severino’s appointment as Chief Executive Officer
Sarepta Therapeutics appointed Dr. Severino as Chief Executive Officer. The 8-K furnishes a press release announcing the appointment but does not provide additional details about Dr. Severino's background, start date, compensation, or the circumstances of any predecessor CEO's departure.
Event · Exhibit 99.1
Sarepta appoints Michael Severino, M.D., as CEO effective July 28, 2026, succeeding retiring CEO Doug Ingram.
Added in current filing · view on EDGAR →
Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition.
Doug Ingram is retiring as CEO and will serve in an advisory capacity through the end of 2026 to facilitate the transition. The Board thanked Ingram for leading Sarepta's evolution into a leader in genetic medicine, including approvals of two exon-skipping treatments and the first one-time gene therapy for Duchenne muscular dystrophy.
Added in current filing · view on EDGAR →
Prior to Tessera, he served as Vice Chairman and President at AbbVie, where he was responsible for research and development and the corporate strategy office. During his tenure at AbbVie, he oversaw a rapid expansion of AbbVie’s pipeline and built critical new capabilities in areas such as genetics and genomics, computational biology, and precision medicine. Severino has made significant contributions to more than a dozen approved therapies including Rinvoq®, Skyrizi®, and Venclexta®
Severino previously served as Vice Chairman and President at AbbVie, overseeing R&D and corporate strategy. He contributed to over a dozen approved therapies including Rinvoq, Skyrizi, and Venclexta, and built leading franchises in hematologic oncology, immunology, and neuroscience. His experience spans 25 years in biopharmaceuticals including senior roles at Amgen and Merck.
Added in current filing · view on EDGAR →
After a comprehensive search, which identified multiple experienced and attractive candidates, the Board is pleased to welcome Mike as Sarepta’s next chief executive officer. Over a distinguished 25-year career in biopharmaceuticals, Mike has demonstrated a combination of scientific depth, development expertise, and proven execution that consistently delivers results
The Board conducted a comprehensive search that identified multiple experienced candidates before selecting Severino. Board Chairperson M. Kathleen Behrens highlighted his scientific depth, development expertise, proven execution, and experience building industry-leading franchises across multiple therapeutic areas as key qualifications for the role.
Added in current filing · view on EDGAR →
I am particularly pleased that Mike inherits a company with a great team, a portfolio of life-changing therapies, a pipeline with exceptional potential and the financial resources to advance that science independently and at scale.
Outgoing CEO Ingram stated that Severino inherits a company with a strong team, portfolio of life-changing therapies, a pipeline with exceptional potential, and financial resources to advance science independently and at scale. This characterizes the company's current operational and financial position as the leadership transition occurs.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify